Lead Product(s): Pegcetacoplan
Therapeutic Area: Hematology Product Name: Empaveli
Highest Development Status: Phase IV Product Type: Peptide
Partner/Sponsor/Collaborator: SFJ Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2021
In the study, EMPAVELI met the primary endpoint, demonstrating superiority to Soliris for the change from baseline in hemoglobin level at Week 16 with an adjusted mean increase of 3.84 g/dL of hemoglobin.